Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RZLTNASDAQ:TERNNASDAQ:UPXINYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRZLTRezolute$4.31-0.5%$3.95$2.22▼$6.19$370.30M1.04586,440 shs803,717 shsTERNTerns Pharmaceuticals$4.00-1.5%$3.32$1.87▼$11.40$354.59M-0.181.49 million shs822,151 shsUPXIUpexi$3.16-5.1%$10.45$1.90▼$22.57$126.26M-0.3942,494 shs2.53 million shsVNRXVolitionRx$0.87+14.2%$0.55$0.40▼$0.94$89.42M1.07203,888 shs205,073 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRZLTRezolute-0.46%+5.90%+12.53%+47.10%+7.75%TERNTerns Pharmaceuticals-1.48%0.00%+32.89%+36.99%-40.03%UPXIUpexi-5.11%-70.71%-68.18%+41.07%-60.49%VNRXVolitionRx+14.21%+29.32%+79.15%+57.82%+37.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRZLTRezolute2.8834 of 5 stars3.61.00.00.03.64.20.0TERNTerns Pharmaceuticals4.325 of 5 stars3.32.00.04.13.33.30.6UPXIUpexi3.1783 of 5 stars3.53.00.00.02.53.30.6VNRXVolitionRx1.578 of 5 stars3.50.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRZLTRezolute 3.14Buy$11.83174.56% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63290.63% UpsideUPXIUpexi 3.00Buy$16.00406.33% UpsideVNRXVolitionRx 3.00Buy$3.50303.23% UpsideCurrent Analyst Ratings BreakdownLatest VNRX, RZLT, UPXI, and TERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.006/10/2025VNRXVolitionRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.004/30/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.004/8/2025VNRXVolitionRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$2.50 ➝ $2.503/31/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/AUPXIUpexi$26M4.61N/AN/A$6.24 per share0.51VNRXVolitionRx$1.31M68.35N/AN/A($0.11) per share-7.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%N/ATERNTerns Pharmaceuticals-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%7/8/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.27N/A∞N/A-2,321.14%N/A-163.39%N/ALatest VNRX, RZLT, UPXI, and TERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRZLTRezoluteN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRZLTRezoluteN/A8.438.43TERNTerns PharmaceuticalsN/A30.8930.89UPXIUpexi0.310.370.24VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRZLTRezolute82.97%TERNTerns Pharmaceuticals98.26%UPXIUpexi5.68%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipRZLTRezolute18.39%TERNTerns Pharmaceuticals1.50%UPXIUpexi31.60%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRZLTRezolute4085.52 million69.79 millionOptionableTERNTerns Pharmaceuticals4087.34 million86.03 millionNot OptionableUPXIUpexi13037.92 million25.93 millionOptionableVNRXVolitionRx80103.02 million80.80 millionOptionableVNRX, RZLT, UPXI, and TERN HeadlinesRecent News About These CompaniesVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx (NYSE:VNRX) Coverage Initiated at Jones TradingJune 10, 2025 | marketbeat.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of StockJune 5, 2025 | insidertrades.comVolition Announces Two Oral Presentations at Asian Meeting of Animal Medicine SpecialtiesJune 4, 2025 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Director Buys $10,800.00 in StockJune 4, 2025 | marketbeat.comVolitionRX shares hold as Benchmark maintains ratingMay 21, 2025 | uk.investing.comVolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of StockMay 20, 2025 | insidertrades.comVolitionRx Limited Announces Successful Detection of Nucleosomes in CatsMay 19, 2025 | prnewswire.comVolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advancesMay 16, 2025 | msn.comVolitionRX Limited (VNRX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comVolitionRx Limited Announces First Quarter 2025 Financial Results and Business UpdateMay 15, 2025 | prnewswire.comVolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business UpdateMay 12, 2025 | prnewswire.comVolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoptionMay 7, 2025 | prnewswire.comVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29, 2025 | prnewswire.comVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comVolitionRx initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationApril 8, 2025 | msn.comEarnings call transcript: VolitionRx revenue beats forecast in Q4 2024April 2, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNRX, RZLT, UPXI, and TERN Company DescriptionsRezolute NASDAQ:RZLT$4.31 -0.02 (-0.46%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$4.43 +0.13 (+2.90%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Terns Pharmaceuticals NASDAQ:TERN$4.00 -0.06 (-1.48%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$4.00 0.00 (0.00%) As of 06/26/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Upexi NASDAQ:UPXI$3.16 -0.17 (-5.11%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.32 +0.16 (+5.06%) As of 05:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.VolitionRx NYSE:VNRX$0.87 +0.11 (+14.21%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.88 +0.01 (+1.04%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
